论文部分内容阅读
目的:应用胰激肽原酶治疗2型糖尿病(T2DM)早期肾病患者,观察尿微量白蛋白及纤维蛋白原(FIB)、C反应蛋白(CRP)变化。方法:T2DM早期肾病患者(尿白蛋白排泄率UAER20~200μg.min-1)70例随机分为胰激肽原酶治疗组40例及非治疗组30例,测定血糖及血脂、UAER、CRP、FIB等。另选30例正常健康者作对照组。结果:血糖、TG、CRP、FIB、UAER在2组均有下降,治疗组与非治疗组比较有统计学意义(P<0.01)。HDL逐渐升高,2组有统计学意义(P<0.05)。结论:胰激肽原酶可在降低TG、CRP、FIB水平的同时,降低UAER水平,使用胰激肽原酶进行干预可有效减轻DN患者微量白蛋白尿。
Objective: To observe the changes of urine microalbumin, fibrinogen (FIB) and C-reactive protein (CRP) in patients with early nephropathy of type 2 diabetes mellitus (T2DM) treated with pancreatic kininogenase. Methods: 70 patients with early diabetic nephropathy (urinary albumin excretion rate UAER20 ~ 200μg.min-1) were randomly divided into 40 cases of pancreatic kallikrein treatment group and 30 cases of non-treatment group. Blood glucose, blood lipid, UAER, CRP, FIB and so on. Another 30 cases of normal healthy control group. Results: The levels of blood glucose, TG, CRP, FIB and UAER decreased in both groups. There was a significant difference between the two groups (P <0.01). HDL gradually increased, two groups were statistically significant (P <0.05). Conclusion: Pancreatic kallikrein can reduce the levels of TG, CRP and FIB and reduce the level of UAER. The intervention of kallikrein can effectively reduce the microalbuminuria in DN patients.